1. Home
  2. CINGW vs ITIC Comparison

CINGW vs ITIC Comparison

Compare CINGW & ITIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • ITIC
  • Stock Information
  • Founded
  • CINGW N/A
  • ITIC 1972
  • Country
  • CINGW United States
  • ITIC United States
  • Employees
  • CINGW 13
  • ITIC N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • ITIC Specialty Insurers
  • Sector
  • CINGW Health Care
  • ITIC Finance
  • Exchange
  • CINGW Nasdaq
  • ITIC Nasdaq
  • Market Cap
  • CINGW N/A
  • ITIC N/A
  • IPO Year
  • CINGW 2021
  • ITIC N/A
  • Fundamental
  • Price
  • CINGW $0.03
  • ITIC $228.34
  • Analyst Decision
  • CINGW
  • ITIC
  • Analyst Count
  • CINGW 0
  • ITIC 0
  • Target Price
  • CINGW N/A
  • ITIC N/A
  • AVG Volume (30 Days)
  • CINGW N/A
  • ITIC 6.4K
  • Earning Date
  • CINGW N/A
  • ITIC 05-02-2025
  • Dividend Yield
  • CINGW N/A
  • ITIC 6.94%
  • EPS Growth
  • CINGW N/A
  • ITIC 43.49
  • EPS
  • CINGW N/A
  • ITIC 16.43
  • Revenue
  • CINGW N/A
  • ITIC $258,077,000.00
  • Revenue This Year
  • CINGW N/A
  • ITIC N/A
  • Revenue Next Year
  • CINGW N/A
  • ITIC N/A
  • P/E Ratio
  • CINGW N/A
  • ITIC $13.90
  • Revenue Growth
  • CINGW N/A
  • ITIC 14.93
  • 52 Week Low
  • CINGW N/A
  • ITIC $146.41
  • 52 Week High
  • CINGW N/A
  • ITIC $290.40
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • ITIC 47.33
  • Support Level
  • CINGW N/A
  • ITIC $223.27
  • Resistance Level
  • CINGW N/A
  • ITIC $236.16
  • Average True Range (ATR)
  • CINGW 0.00
  • ITIC 7.04
  • MACD
  • CINGW 0.00
  • ITIC 0.23
  • Stochastic Oscillator
  • CINGW 0.00
  • ITIC 59.66

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.

Share on Social Networks: